Citigroup
MACK

Citigroup’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Citigroup’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-4,449
Closed -$17K – 8018
2018
Q2 		$17K Buy
+4,449
New +$29.5K ﹤0.01% 7011
2018
Q1 		– Sell
-2,161
Closed -$17K – 7858
2017
Q4 		$17K Buy
2,161
+1,716
+386% +$16K ﹤0.01% 6826
2017
Q3 		$5K Sell
445
-1,843
-81% -$19.4K ﹤0.01% 6881
2017
Q2 		$22K Sell
2,288
-2,313
-50% -$47.2K ﹤0.01% 6242
2017
Q1 		$111K Sell
4,601
-572
-11% -$14.3K ﹤0.01% 5134
2016
Q4 		$166K Buy
5,173
+3,419
+195% +$146K ﹤0.01% 5441
2016
Q3 		$88K Buy
+1,754
New +$72.8K ﹤0.01% 5295

Other funds holding MACK

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
RA
Rise Advisors Rochester, New York $355M AUM 20.51% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Citigroup's MACK Position: Q2 2024 in Review

Citigroup sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 1,956 shares — an estimated $28.9K sold.

Citigroup first reported a position in MACK in Q2 2013 and held it in 29 quarters. The position peaked at $1.83M in Q4 2016. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.

  • Citigroup reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Citigroup sold 1,956 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $28.9K.
  • Citigroup first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 29 quarters.
  • Citigroup's Merrimack Pharmaceuticals, Inc. position peaked at $1.83M in Q4 2016.
  • 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.

Based on Citigroup's 13F filing for Q2 2024, filed 12 Aug 2024.